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Journal of the American Heart Association
SYSTEMATIC REVIEW AND META-ANALYSIS

Association of Nonacute Opioid Use and
Cardiovascular Diseases: A Scoping Review
of the Literature
Jade H. Singleton , MPH, PhD; Erin L. Abner
Anna M. Kucharska-Newton , PhD

, PhD; Peter D. Akpunonu

, MD;

BACKGROUND: In this scoping review, we identified and reviewed 23 original articles from the PubMed database that investigated the relationship between nonacute opioid use (NOU) and cardiovascular outcomes.
METHODS AND RESULTS: We defined NOU to include both long-term opioid therapy and opioid use disorder. We summarized
the association between NOU and 5 classes of cardiovascular disease, including infective endocarditis, coronary heart disease (including myocardial infarction), congestive heart failure, cardiac arrythmia (including cardiac arrest), and stroke. The
most commonly studied outcomes were coronary heart disease and infective endocarditis. There was generally consistent
evidence of a positive association between community prevalence of injection drug use (with opioids being the most commonly injected type of drug) and community prevalence of infective endocarditis, and between (primarily medically indicated)
NOU and myocardial infarction. There was less consensus about the relationship between NOU and congestive heart failure,
cardiac arrhythmia, and stroke.
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CONCLUSIONS: There is a dearth of high-quality evidence on the relationship between NOU and cardiovascular disease. Innovative
approaches to the assessment of opioid exposure over extended periods of time will be required to address this need.
Key Words: cardiovascular disease ■ epidemiology ■ opioids

E

xposure to opioid drugs in the United States1,2 has
increased exponentially over the past 30 years.3,4
This includes use of prescription opioids for medical purposes as directed by a physician—
such as
treatment of opioid dependence, cancer-related pain,
or noncancer chronic pain—as well as non–medically
indicated use of prescription opioids and illicit opioid
use. Opioid treatment, initially restricted to patients with
cancer, expanded over time to include the treatment
of non–cancer-related pain. A growing awareness of
the problem of undertreated pain resulted in standards,
issued by the Joint Commission on Accreditation of
Healthcare Organizations in 2001, requiring greater
monitoring and treatment of pain.5,6 Pharmaceutical
companies aggressively marketed opioid medications

for treatment of chronic pain,7 citing flawed research
studies as evidence of the safety of these medications.8
As a result of these and other factors, opioid prescribing in the United States increased nearly 7-fold between
1997 and 2007. The increase in opioid availability was
accompanied by steep increases in fatal and nonfatal
overdoses9 and opioid use disorder (OUD).2,10
Long-term opioid therapy—such as for the treatment of chronic pain or opioid addiction—has been defined as use of opioids on most days for >3 months.11
Long-term exposure to opioids may also result from
the nonmedical use of prescription or illicit opioids because of dependence or addiction, leading to an OUD.
We use the term nonacute opioid use (NOU) to encompass both long-term opioid therapy and OUD.
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A Scoping Review of the Nonacute OUD and CVD

We identified original, peer-reviewed research articles on the relationship between NOU involving any
prescription medication containing opioids, or any illicit opioid drug, and CVD. We conducted a keyword
search and a Medical Subject Headings (MeSH) term
search of the PubMed database for articles published
on or before September 2, 2019. The keyword search
included the following strings and logic: (“Heart Failure”
OR “Endocarditis” OR “Myocardial infarction” OR “Atrial
fibrillation” OR “cardiac arrhythmia” OR “myocardial
ischemia” or “coronary heart disease” or “cardiac arrest” or “stroke” or “coronary artery disease”) AND
Opioid AND epidemiology. For the MeSH term search,
the strings and logic were: (“Analgesics, Opioid” [Majr]
OR “Opioid-
Related Disorders/epidemiology” [Majr])
AND (“Cardiovascular Diseases/epidemiology” [Majr]
OR “Stroke/epidemiology” [Majr]). We included the
term epidemiology in both keyword and MeSH term
searches to exclude basic science and nonhuman
studies. Additional articles were identified from the reference lists of retrieved articles.

Nonstandard Abbreviations and Acronyms
ER-HPO
IE
NOU

extended-release high-potency opioid
infective endocarditis
nonacute opioid use
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Researchers have begun to investigate possible effects of long-term opioid use on health outcomes other than addiction and misuse. Of specific
interest is cardiovascular disease, which remains a
leading cause of death, physician and emergency
department visits, and hospitalization in the United
States.12,13 Trends in hospitalized cases of infective
endocarditis14 have been shown to mirror trends
in opioid overdose and injection drug use (IDU).15
Observational studies have also reported an association of opioid drug use with increased risk of cardiovascular events, including myocardial infarction (MI)
and heart failure.
However, it is unclear what the biological pathways between long-term exposure to opioids and
cardiovascular disease (CVD) might be. Opioid receptors have been discovered in the heart, and their
activation by short-
term administration of opioid
drugs before acute ischemic events has been shown
to have a cardioprotective effect.16 However, the association between chronic opium use and increased
levels of low-
density lipoproteins and triglycerides
could provide a pathway to coronary artery disease.17,18 High and increasing prevalence of NOU and
a sustained high burden of cardiovascular disease
have prompted this scoping review of the literature to
systematically examine the association of NOU with
cardiovascular outcomes.

Inclusion and Exclusion Criteria
We included original articles that investigated the association of NOU with ≥1 of the following 5 cardiovascular outcomes: infective endocarditis (IE); coronary
heart disease, including MI; congestive heart failure;
cardiac arrythmia, including cardiac arrest; and stroke.
We excluded studies that lacked an appropriate comparison group. In most cases, this meant individuals
who did not experience NOU. In the case of endocarditis, it meant either individuals who did not inject opioids or a time period during which injection opioid use
was expected to be substantially lower because of a
policy change. The details of inclusion and exclusion
are listed in Table 1.
One author (J.S.) reviewed the entire list of identified
references, while 2 authors (A.K.N. and E.L.A.) each
reviewed a mutually exclusive half of the references.
Disagreement in the classification of records by the 2
independent reviewers was adjudicated by group consensus. A flow diagram summarizes article selection
procedures (Figure).

METHODS
The data that support the findings of this study are
available from the corresponding author upon reasonable request.
Table 1. Inclusion and Exclusion Criteria for Studies
Inclusion Criteria
• Investigates the relationship between a history of long-term (medical or
nonmedical) exposure to opioids (prescription or illicit) and subsequent
cardiovascular disease
• Investigates the relationship between history of opioid use and
cardiovascular outcomes following a (not necessarily cardiovascular)
medical procedure (eg, kidney transplant, orthopedic surgery)

Exclusion Criteria
•
•
•
•
•
•
•

Basic science studies
Nonhuman studies
Case study or case series
Review articles
Nonoriginal research including editorials, letters, and protocols
Short term opioid use
Studies of the effect of brief exposures to opioid medications (eg, for
analgesia or anesthesia related to a surgical procedure or other medical
events)
• Studies of the relationship between opioid use and any cardiovascular
events other than those of interest
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294 records idenfied through
PubMed keyword search

39 records idenfied through
PubMed MESH search
24 arcles that belong to
reviews, single case, series
study were excluded

270 arcles that belong to
reviews, single case, series
study were excluded

15 arcles le

24 arcles le

1 arcle that has no access
to full text was removed

2 arcle that has no access
to full text were removed

14 arcles le

22 arcles le

5 duplicate arcles were excluded

31 studies included in the full-text review
Downloaded from http://ahajournals.org by on January 31, 2022

8 arcles were excluded due to lack of
informaon on study design
23 studies included in the final review
Figure. Flow diagram of included studies.
MESH indicates Medical Subject Headings.

RESULTS
A total of 39 articles were identified from the MeSH
term search and 294 articles from the keyword
search. After excluding reviews and case series, articles that did not address NOU or any of our outcomes
of interest, those that did not include a comparison
group, and those for which full text could not be retrieved, and after and resolving duplicates that were
retrieved through both search protocols, 23 studies
remained for review. Fourteen articles were from the
United States, 2 from Iran, 2 from Canada, and 1
each from of the following countries: United Kingdom,
Italy, Germany, Spain, and Taiwan. There were 10
cohort studies,19–28 5 case-
control studies,29–33 3
34–36
cross-sectional studies,
and 5 trend analyses37–41

(Table 2, Table S1). All included studies used retrospective designs.

Myocardial Infarction
Of the 10 studies that reported on the association of
opioid use with MI, 4 used data from retrospective
cohorts,19,34–36 2 were cross-
sectional studies,23,25
and 4 were nested case-
control studies.29,31–33
Among older adults with chronic obstructive pulmonary disease, when restricting to opioid-
only
formulation, positive associations were observed
for coronary artery disease (CAD)-related mortality
(hazard ratio [HR], 1.83; 95% CI, 1.32–2.53), and for
CAD-related emergency room visit or hospital admission (HR, 1.38; 95% CI, 1.08–1.77). Carman et al19

J Am Heart Assoc. 2021;10:e021260. DOI: 10.1161/JAHA.121.0212603
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RCS

Jain, 2008,20 United
States

Keeshin, 2016,21
United States

RCS

CC

RTA

Hartman, 2016,38
United States

Jobski, 2017,
Germany

RTA

Gray, 2018,37 United
States

29

RCS

Carman, 2011,19
United States

Study Design

RTA

41

Bates, 2019, United
States

Study

1999–2009

2006–2011

1996–2003

2009–2014

2000–2016

2002–2005

2008–2015

Year Frame

392

309 936

238

127

510

148 657

462

N

Myocardial infarction

High-dose chronic opioid therapy for
nonmalignant pain

Positive opiate toxicology
screens

Stroke

Recent switch of substance (referent: past
use)

Injection opioid use

Stroke

Recent discontinuation of any ER-HPO
(referent: past use)

Endocarditis

Stroke

Current or recent use of ER-HPO (referent:
past use)

HCV antibody prevalence

Myocardial infarction

Recent switch of substance (referent: past
use)

Injection opioid use

Myocardial infarction

Recent discontinuation of any ER-HPO
(referent: past use)

Injection opioid use V

Myocardial infarction

Tricuspid valve IE

Heroin
Current or recent use of ER-HPO (referent:
past use)

Mitral valve IE

IV

Tricuspid valve IE

Injection drug use

Endocarditis

Injection drug use III

Injection drug use II

Endocarditis

Myocardial infarction

Low-dose chronic opioid therapy for
nonmalignant pain

Injection drug use (no mention of opioid
name)

Myocardial infarction

Endocarditis

Outcome

Overall chronic opioid I therapy for
nonmalignant pain

Illicit drug use

Exposure

(Continued)

Positive opiate toxicology screens
increase 6-fold

HCV antibody prevalence increase
3-fold

Endocarditis cases increase 2-fold

OR, 1.19; 95% CI, 0.89–1.58

OR, 1.14; 95% CI, 1.02–1.27

OR, 0.95; 95% CI, 0.88–1.02

OR, 1.38; 95% CI, 1.02–1.86

OR, 1.11; 95% CI, 0.98–1.25

95% CI, 1.09–1.26

OR, 1.17,

OR, 4.37; P=0.001

OR, 4.37; P=0.001

OR, 4.37; P=0.001

Percentage of endocarditis
increases from 14% in 2009 to 56%
in 2014

Prevalence ratio of IDU per year,
1.09; 95% CI, 1.05–1.14

IRR, 1.89; 95% CI, 1.54–2.33

IRR, 1.21; 95% CI, 1.02–1.45

IRR, 2.66; 95% CI, 2.3–3.08

Relative risk increase, 0.06%;
P=0.001

Effect Estimate

Table 2. Selected Major Studies of the Association of Nonacute Opioid Use With Endocarditis, MI, Congestive Heart Failure, Arrhythmia, and Stroke
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RCS

RTA

CC

RCS

Lentine, 2015,22
United States

Lewer, 2017,39 United
Kingdom

Li, 2013,31 United
States

Marmor, 2004,23
United States

CS

Study Design

CC

34

Lee, 2013,30 Taiwan

Khodneva, 2016,
United States

Study

1998

1990–2008

1997–2016

2006–2008

1998–2010

2003–2007

Year Frame

98

56 590

1 052 444

16 322

6040

29 025

N

Cardiac arrest

Pretransplant prescription narcotic use with
deceases donor

Myocardial infarction
Myocardial infarction

Morphine prescription
Meperidine prescription

Coronary artery disease

OR, 2.15; 95% CI, 1.24 to 3.74

Myocardial infarction

Buprenorphine prescription

Serologic evidence of methadone or opiates
(as proxy for long-term exposure to opioids)

OR, 1.71; 95% CI, 1.09 to 2.68

Myocardial infarction

Any opioid prescription cumulative use >50
Rx

(Continued)

OR, 0.43; 95% CI, 0.2 to 0.94

OR, 1.46; 95% CI, 1.22 to 1.76

OR, 1.25; 95% CI, 1.11 to 1.4

OR, 1.38; 95% CI, 1.28 to 1.49

Myocardial infarction

Any opioid prescription cumulative use
11–50 Rx

OR, 1.28; 95% CI, 1.19 to 1.37

Myocardial infarction

Hospital admissions for infections
related to injection drug use
increased annually from 2012 to
2016

HR, 1.31; 95% CI, 0.85 to 2.01

HR, 1.83; 95% CI, 0.94 to 3.54

HR, 5.58; 95% CI, 2.19 to 14.21

HR, 1.38; 95% CI, 0.14 to 13.42

OR, 2.9; 95% CI, 1.58 to 5.35

OR, 4.24; 95% CI, 1.03 to 17.4

OR, 3.02; 95% CI, 1.68 to 5.42

OR, 1.13; 95% CI, 0.97–1.31

HR, 0.7; 95% CI, 0.5–0.97

HR, 1.38; 95% CI, 1.05–1.82

HR, 1.03; 95% CI, 0.83–1.26

HR, 1.04; 95% CI, 0.78–1.38

Effect Estimate

Any opioid prescription VII at current use
(≤30 d)

Endocarditis

Cardiac arrest

Pretransplant prescription narcotic use with
living donor

Injection opioid use

Ventricular arrhythmia

Pretransplant prescription narcotic use with
deceased donor

Stroke: ischemic

Treatment with morphine for prostate
cancer-related pain

Ventricular arrhythmia

Stroke: hemorrhagic

Treatment with morphine for prostate
cancer-related pain

Pretransplant prescription narcotic use with
living donor

Stroke: all stroke

Treatment with morphine for prostate
cancer-related pain

Coronary artery disease in male

Prescription opioid use for nonmalignant
chronic pain
Stroke: all stroke

Coronary artery disease in
female

Prescription opioid use for nonmalignant
chronic pain

Treatment with morphine for all cancer-
related pain

Coronary artery disease in all

Prescription opioid use for nonmalignant
chronic pain

Outcome
Stroke

VI

Exposure
Prescription opioid use for nonmalignant
chronic pain
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RCS

CC

CC

CS

RCS

CS

RTA

Omran, 2019,27 United
States

Pontes, 2018,1 Spain

Roberto, 2015,33 Italy

Sadeghian, 2009,35
Iran

Solomon, 2010,28
United States

Vozoris, 2017,36
Canada

Weir, 2019,40 Canada
2006–2015

2008–2013

1996–2005

2006–2008

2002–2012

2008–2012

1993–2015

2010–2011

2002–2011

2013–2017

Year Frame

60 529

149 094

31 375

4398

12 483

22 652

5283

200

9 307 348

1921

N

Intervention: removal of controlled-release
oxycodone from Canadian market (2011 Q4)

Endocarditis

Heart failure
Coronary artery disease

Incident opioid use

Nonspecific
Incident opioid use IX

Incident opioid therapy VIII for nonmalignant
pain

Arrhythmia and cardiac arrest

Opioid dependence (according to DSM-IV
criteria)

Myocardial infarction

Past use

Myocardial infarction

Myocardial infarction

Recent use

Opioid dependence (according to DSM-IV
criteria)

Myocardial infarction

No quantitative estimates provided

HR, 2.15; 95% CI, 1.5 to 3.09

HR, 0.84; 95% CI, 0.73 to 0.97

RR, 1.62; 95% CI, 1.27 to 2.06

RR, 0.65; 95% CI, 0.43 to 1.03

RR, 0.34; 95% CI, 0.02 to 3.23

OR, 1.13; 95% CI, 0.86 to 1.48

OR, 1.12; 95% CI, 0.8 to 1.55

OR, 1.22; 95% CI, 0.92 to 1.63

OR, 1.13; 95% CI, 1.03 to 1.24

Percentage change from 2008
to 2015, 20.3%; 95% CI, 10.5 to
30.9%

Stroke

Myocardial infarction

Stroke percentage change from
1993 to 2008, 1.9%; 95% CI, −2.2%
to 6.1%

OR, 21.9; 95% CI, 9.58 to 50.01

OR, 1.9; 95% CI, 1.3 to 2.6

Endocarditis percentage change,
238%

Effect Estimate

Stroke

Arrhythmia and cardiac arrest

Myocardial infarction

Endocarditis

Outcome

Current use of acetaminophen or/and an
acetaminophen-codeine combination
(0–90 d) (referent=nonuse, defined as more
than 365 d since last use)

Opioid analgesic therapy for osteoarthritis-
related pain

Opioid

Opium addiction (as defined by DSM-IV
criteria for substance dependence)

Opioid use disorder (opioid abuse or
dependence)

Injection drug use

Exposure

Opioid names listed in the Exposure column in Table 2 with roman numerals are listed in Table S1. CC indicates case control; CS, cross sectional; DSM-IV, Diagnostic and Statistical Manual, 4th edition; ER-HPO,
extended-release high-potency opioid; HCV, hepatitis C virus; HR, hazard ratio; IRR, incidence rate ratio; MI, myocardial infarction; OR, odds ratio; RCS, retrospective cohort study; RR, relative risk; and RTA, retrospective
trend analysis.

RCS

Mirzaiepour, 2012,26
Iran

RCS

Study Design

RCS

24

Menendez, 2015,25
United States

Meisner, 2019,
United States

Study
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reported a positive association between chronic opioid therapy for nonmalignant pain and MI incidence
in a commercially insured cohort, with greater risk
observed at higher doses (incidence rate ratio, 2.66;
95% CI, 2.30–3.08). Within a group of patients who
underwent coronary artery bypass grafting,35 a relative risk of 0.34 (95% CI, 0.02–2.32), was reported for
perioperative MI, among patients with preoperative
opioid dependence. However, the extremely wide CI
indicates the possibility of a sparse data bias.
In a case-control study of primary care patients with
physician-diagnosed osteoarthritis,32 Pontes et al reported
a positive association between the odds of MI and use of
opioid analgesics for treatment of osteoarthritis (odds ratio
[OR], 1.13; 95% CI, 1.03–1.24), with odds increasing as the
mean monthly dose of opioids increased. Jobski et al29
reported associations with recent (within 30 days of index
MI) discontinuation of extended-release high-potency opioid (ER-HPO) therapy (OR, 1.11; 95% CI, 0.98–1.25) and
recent (within 30 days of index MI) switch (OR, 1.38; 95%
CI, 1.02–1.86) of ER-HPO medication type. Within a group
of general practice patients with osteoarthritis, Roberto
et al33 reported no statistically significant association with
acetaminophen–codeine for treatment of osteoarthritis pain
(OR, 1.22; 95% CI, 0.92–1.63). Li et al31 reported a positive
association between MI and current opioid use (OR, 1.28;
95% CI, 1.19–1.37), 2-year cumulative prior use consisting
of 11 to 50 prescriptions (OR, 1.38; 95% CI, 1.28–1.49), and
2-year cumulative prior use consisting of >50 prescriptions
(OR, 1.25; 95% CI, 1.11–1.40).
Findings from Marmor’s cross-sectional study of serologic evidence of methadone or opioid use at autopsy,
and its relationship to coronary artery plaque, suggest
a protective effect with respect to CAD (OR, 0.43; 95%
CI, 0.20–0.94).23 However, the study did not provide
information on duration of opioid use or of methadone
treatment of opioid addiction. Among hospital inpatients undergoing major elective orthopedic surgery,
Menendez et al25 reported a positive association between preoperative opioid abuse or dependence and
in-hospital MI (OR, 1.90; 95% CI, 1.30–2.60).
Conversely, data from the REGARDS (Reasons for
Geographic And Racial Differences in Stroke) study34
suggest no association overall between prescription
opioid use for nonmalignant chronic pain and coronary
heart disease over the course of 4 to 7 years of follow-up
(HR, 1.03; 95% CI, 0.83–1.26). In an analysis stratified by
sex, the authors report a modest increase in coronary
heart disease risk among women (HR, 1.38; 95% CI,
1.05–1.82), but a decrease in risk among men (HR, 0.70;
95% CI, 0.50–0.97) with evidence of opioid use.

Heart Failure
There were no studies of NOU and heart failure identified in our search.

A Scoping Review of the Nonacute OUD and CVD

Arrhythmia
Of the 3 studies that reported on the association of
opioid use with arrhythmia, 2 used data from retrospective cohorts,22,35 and 1 was a cross-
sectional
study.26 In a cohort of hospital patients who underwent coronary artery bypass surgery, Sadeghian et
al35 reported a protective association between atrial fibrillation and opium addiction that was not statistically
significant (OR, 0.65; 95% CI, 0.43–1.03). In hospital
patients admitted with acute MI, Mirzaiepour et al26
reported a strong, positive association between postMI arrhythmia and opium addiction (OR, 21.9; 95% CI,
9.58–50.0). In a cohort of patients undergoing kidney
transplantation, Lentine et al22 reported a positive association between ventricular arrhythmia and pretransplant opioid use at a dose >23.8 mg/kg morphine
equivalents (HR, 5.58; 95% CI, 2.19–14.21).

Stroke
Of the 4 studies reporting on the association of opioid
use and ischemic or hemorrhagic stroke, 2 used data
from a retrospective cohort,27,34 and 2 were nested
case-control studies.29,30 Jobski et al29 reported an
association with recent (within 30 days of index MI)
discontinuation of ER-HPO therapy (OR, 1.14; 95% CI,
1.02–1.27). No association was reported for current
opioid use or recent switch of opioid type. Omran et
al27 reported percentage of stroke among hospitalized
patients changed 20.3% (95% CI, 10.5%–30.9%) from
2008 to 2015 with the combination of opioid abuse.
Khodneva et al reported no association between prescription opioid use for nonmalignant chronic pain and
stroke over a median34 of 5.2 (1.8) years of follow-up
in the REGARDS study (HR, 1.04; 95% CI, 0.78–1.38).
Lee et al30 reported a positive association between
morphine use for cancer-related pain and hemorrhagic
stroke (OR, 1.36; 95% CI, 1.02–1.82) but not ischemic
stroke (OR, 1.08; 95% CI, 0.92–1.27). When restricted
to patients with prostate cancer only, the association
with hemorrhagic stroke was higher (OR, 4.24; 95% CI,
1.03–17.4), and a significant association with ischemic
stroke was reported (OR, 2.90; 95% CI, 1.58–5.35).

Infective Endocarditis
Seven studies investigated the association between
opioid use and IE. Five of these were trend analyses,
of which 4 reported a temporal association between
IDU and IE,24,37–40 and 1 reported a temporal association between mixed drug use and IE.41 Jain and colleagues20 reported an association between IDU and
tricuspid valve IE. Keeshin and colleagues21 suggested
that increases in hospital admissions for IE may provide an indirect surveillance marker for IDU within the
surrounding community.

J Am Heart Assoc. 2021;10:e021260. DOI: 10.1161/JAHA.121.0212607
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There has been a growing interest in the possible cardiovascular effects of opioid drugs. Khodneva et al34
described self-reported, baseline CVD in a cohort of
community-dwelling adults consisting of 1851 participants with prescription opioid use and 27 174 nonusers.
They found that coronary heart disease (22.8% versus
17.4%), stroke (13.2% versus 8.5%) and corrected QT
interval prolongation (3.3% versus 2.8%) were more
commonly reported by participants with prescription
opioid use. Studies have investigated the link between
methadone treatment for OUD and elongation of the
QT interval/torsade de pointes, which can lead to cardiac arrhythmias and cardiac arrest.42,43 Solomon et
al28 reported different relative risk of cardiac events
after the start of different opioid therapy. Moreover,
several studies have reported a small or moderate increase in the risk of MI in people with chronic exposure
to opioids attributable to abuse/dependence or long-
term opioid therapy for chronic pain.19,25,46 Conversely,
it has been suggested that long-term opiate exposure
may mitigate the severity of coronary artery disease.23
We set out to summarize systematically previous
research on the association between NOU and 5
CVD outcomes. The amount and strength of the evidence varied across the outcomes. The most commonly studied outcomes were MI (10 reports) and
IE (7 reports). Across studies included in this review
was generally consistent evidence of a positive association between community prevalence of injection
drug use (with opioids being the most commonly injected type of drug) and community prevalence of IE,
and between nonacute opioid exposure (primarily for
medical reasons) and MI incidence. The other 4 outcomes were less commonly studied (3 reports each
for CAD, arrhythmia, and stroke; 1 for heart failure),
and there was less consensus about their relationship
with opioid use. Many of the studies, for all outcomes,
lacked detailed information on the duration and dose
of opioid exposure. Several studies have reported a
temporal association between the prevalence of IDU
and the prevalence of IE in a community, suggesting
an increase in the prevalence of IE with increasing
prevalence of IDU. The sharing of needles and other
materials promotes the spread of microbial infections,
with IE cases frequently resulting from staphylococcal
infection.45 Prescription opioids and heroin are among
the most commonly injected drugs.46 Thus, increasing
exposure to opioids in a population can lead to greater
prevalence of IE, by increasing the prevalence of IDU
within that population.
CAD is the most common cause of MI but is directly observable only by invasive procedures, such as
cardiac catheterization or coronary angiogram, or at
autopsy. This may explain why we identified 7 studies
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with MI as the end point but only 3 with CAD. Only
4 studies19,29,31,33 described detailed assessment of
dose and duration of opioid exposure, and all of these
studies reported an association between opioid use
and MI.
Cardiac opioid receptors have been identified,47 but
possible biological pathways between NOU and MI
or CAD are still not well understood. Li et al31 speculated about possible relationships between opioids,
hormones (including testosterone), and coronary atheroma, but their study did not explore these connections. Although some studies, such as that of Tanaka et
al,48 attempt to address from a molecular perspective
the role of endogenous and exogenous opioids and
cardiac opioid receptors in limiting cardiac damage
in patients with acute MI (ischemic preconditioning,
opioid-induced cardio protection), our findings suggest
that long-term opioid exposure is associated with an
increase in the incidence of acute MI.
In a systematic review of opioid use and arrhythmia,
Behzadi et al49 reported that some opioids, including
methadone, tramadol, and oxycodone, are associated
with increased risk of long QT syndrome, which in turn
may lead to dangerous arrhythmias including torsade
de pointes. While arrhythmia was one of the cardiovascular conditions included in our review, we found
only 3 studies of the relationship between NOU and
cardiac arrhythmia that met our inclusion criteria. Our
initial query returned a number of articles on opioids
and the QT interval, which, upon review, turned out to
lack an appropriate control group. As a result, those
studies were excluded. Moreover, we excluded studies
of arrhythmias associated with acute opioid exposure
as in, for example, studies conducted among patients
undergoing surgery or patients with acute MI. Thus,
although there is a body of evidence linking use of
certain opioids with the long QT syndrome, we found
little high-
quality, epidemiologic evidence examining
directly the association of NOU with cardiac arrhythmias per se. This appears to be a gap in need of future
attention.
We found no studies that addressed the association of NUO with the risk of stroke or heart failure in a
general cohort that included a reliable assessment of
dose and duration of opioid use. The identified studies had ≥1 serious limitations, including highly selective
cohorts or a primary focus on short-term exposures,
such as recent use, change of medication, discontinuation of medication, or inadequate assessment of dose
and duration. There remains a need for high-quality
studies examining the relationship between NOU and
stroke and congestive heart failure.
Much of the research on opioids and CVD has focused on acute exposures related to surgical procedures or other treatment for acute medical conditions.
Examples include opioids used for anesthesia during
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surgery or for postoperative analgesia and morphine
as part of treatment for acute MI. There has been
relatively little high-quality research on nonacute opioid exposure and its relationship with cardiovascular conditions. A significant challenge for this type of
research is the accurate assessment of the duration
and intensity of opioid exposure over an extended
period of time. For example, it is estimated that the
period between the appearance of major risk factors
for CAD—
high serum cholesterol and high systolic
blood pressure—and their effects on mortality may be
≥10 years.50 Exposure to prescription opioids is well
documented in administrative claims databases, but
members may be lost to follow-up if they change insurance plans. Moreover, exposure to nonmedical use
of opioids is practically impossible to assess through
secondary data sources.
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In conclusion, this review of the literature on the association of NOU with the risk of cardiovascular events
provides summative evidence that such exposure
poses a risk not only for cardiac disorders associated
with infections caused by needle reuse, such as infective endocarditis, but may also predispose people to
chronic cardiovascular disorders, including MI and arrhythmias. There is a dearth of high-quality evidence
on the relationship between NOU and CVD. Many of
the identified studies lacked detailed information on
the duration and intensity of opioid exposure and all
were retrospectively conducted. This is understandable, as the challenges to accurate assessment of NOU
are considerable. Innovative approaches to opioid exposure assessment will be required.
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Table S1. Specific opioids used in the 23 reviewed studies (cf Table 2).
References Opioid name
Codeine, codeine, dihydrocodeine, dihydrocodone, fentanyl, hydrocodone,
I
hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone,
oxymorphone, propoxyphene, tramadol,
Heroin, oxycodone, oxymorphone
II
Heroin and methadone
III
Morphine, oxycodone, oxycodone-naloxone, hydromorphone, tapentadol, fentanyl,
IV
Buprenorphine
Heroin
V
VI
Diphenoxylate, hydrocodone, hydromorphone, meperidine, morphine sulfate,
oxycodone, pentazocine, tramadol, fentanyl, codeine
VII
Any prescribed opioid: buprenorphine, morphine, meperidine, tramadol, codeine,
dihydrocodeine, propoxyphene, meptazinol
VIII
Hydrocodone bitartrate, codeine phosphate, oxycodone hydrochloride, propoxyphene
hydrochloride, tramadol hydrochloride
Anileridine, codeine phosphate, hydromorphone HCL, morphine HCL, meperidine HCL,
IX
oxycodone HCL, codeine sulfate, codeine phosphate, acetaminophen-caffeinecodeine, acetaminophen-codeine phosphate, fentanyl transdermal, acetaminophencodeine, acetylcalicylic acid-codeine-caffeine, acetylsalicylic acid-codeine, oxycodoneHCL-acetaminophen, oxycodone HCL-acetylsalicylic acid, morphine HCL, morphine
sulfate
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